Open AccessSurvival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer
Author(s) -
Risa Liang Wong,
Mai T. Duong,
Catherine M. Tangen,
Neeraj Agarwal,
Heather H. Cheng,
Nicholas J. Vogelzang,
Maha Hussain,
Ian M. Thompson,
David I. Quinn,
Evan Y. Yu
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0210-x
Subject(s) - medicine , prostate cancer , oncology , androgen deprivation therapy , proportional hazards model , urology , prostate specific antigen , cancer
Cixutumumab, a monoclonal antibody targeting insulin-like growth factor I receptor, did not improve undetectable prostate-specific antigen (PSA) rate at 28 weeks when combined with androgen deprivation in the randomized phase II SWOG S0925 trial for patients with new metastatic hormone-sensitive prostate cancer. We now present mature survival analyses, along with pre-specified secondary and exploratory endpoints.